Granted Patent
B2
US 12,364,758 · App. 17/361,477 · Granted Jul 22, 2025
Use of leukemia-derived cells in ovarian cancer vaccines
Inventors:
Erik Hans Manting (Leiden, NL); Satwinder Kaur Singh (Leiden, NL); Jeroen Rovers (Leiden, NL)
Assignee:
MENDUS B.V.
A61K40/4257A61K40/19A61K40/24A61K40/424A61K40/4243A61K40/427A61P35/00A61K2039/545A61K2039/55A61K2039/585A61K2039/892A61K40/50A61K2239/31A61K2239/38A61K2239/59
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.
Claims (18)
1. A method of preventing or delaying recurrence of ovarian cancer in a subject comprising:
selecting a subject previously diagnosed with ovarian cancer, wherein the subject is in remission following an initial treatment for the ovarian cancer selected from the group consisting of debulking surgery, chemotherapy, and radiation therapy; and
administering to the subject an effective amount of an immunogenic composition comprising a mature dendritic cell differentiated from the precursor DCOne cell line as deposited under the conditions of the Budapest treaty with the DSMZ under accession number DSMZ ACC3189, wherein the mature dendritic cell is CD34-positive, CD1a-positive, and CD83-positive and is inactivated,
thereby preventing or delaying recurrence of ovarian cancer in the subject.
2. The method of claim 1 , wherein:
the immunogenic composition is formulated for intradermal administration; and
the administration is intradermal.
3. The method of claim 1 , wherein the administering is performed within about two weeks to about six months after the initial treatment for the ovarian cancer.
4. The method of claim 1 , wherein the administering is performed within about two weeks to about one month after the initial treatment for the ovarian cancer.
5. The method of claim 1 , wherein the subject exhibits an elevated serum level of one or more markers selected from the group consisting of CA-125, transferrin, transthyretin, apolipoprotein A1 (apoA1), beta-2 microglobulin (B2M), human epididymis protein 4 (HE4), human chorionic gonadotropin (HCG), alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), inhibin, estrogen, and testosterone, relative to the serum level of the one or more markers in a subject not having ovarian cancer.
6. The method of claim 1 , comprising administering to the subject four doses of the immunogenic composition, wherein each of the four doses comprises about 25 million of the mature cells.
7. The method of claim 6 , further comprising administering to the subject two additional doses of the immunogenic composition, wherein each of the two additional doses comprises about 10 million of the mature cells.
8. The method of claim 1 , wherein the ovarian cancer is a high grade serous ovarian cancer.
9. The method of claim 1 , wherein the initial treatment comprises administering to the subject carboplatin and/or paclitaxel.
10. The method of claim 1 , wherein the initial treatment comprises primary debulking surgery combined with adjuvant chemotherapy.
11. The method of claim 1 , wherein the initial treatment comprises primary debulking surgery combined with six cycles of adjuvant chemotherapy.
12. The method of claim 1 , wherein the initial treatment comprises neoadjuvant chemotherapy and interval debulking surgery.
13. The method of claim 12 , wherein the initial treatment comprises three cycles of neoadjuvant chemotherapy and interval debulking surgery.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 14, 2021
From: MANTING, ERIK HANS; SINGH, SATWINDER KAUR; ROVERS, JEROEN
To: DCPRIME B.V.
Reel/Frame 057793/0736 →
Continuity (3)
Provisional Application
63111390
· Nov 9, 2020
Provisional Application
63046520
· Jun 30, 2020
References Cited (400)
US 4690915A
· Rosenberg
· 1987
[cited by applicant]
US 4797368A
· Carter et al.
· 1989
[cited by applicant]
US 4956778A
· Naito
· 1990
[cited by applicant]
US 5091513A
· Huston et al.
· 1992
[cited by applicant]
US 5132405A
· Huston et al.
· 1992
[cited by applicant]
US 5139941A
· Muzyczka et al.
· 1992
[cited by applicant]
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5876989A
· Berg et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 5993434A
· Dev et al.
· 1999
[cited by applicant]
US 5994136A
· Naldini et al.
· 1999
[cited by applicant]
US 6013516A
· Verma et al.
· 2000
[cited by applicant]
US 6054297A
· Carter et al.
· 2000
[cited by applicant]
US 6080840A
· Slanetz et al.
· 2000
[cited by applicant]
US 6181964B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6207156B1
· Kuchroo et al.
· 2001
[cited by applicant]
US 6233482B1
· Hofmann et al.
· 2001
[cited by applicant]
US 6516223B2
· Hofmann
· 2003
[cited by applicant]
US 6534055B1
· June et al.
· 2003
[cited by applicant]
US 6567694B2
· Hayakawa
· 2003
[cited by applicant]
US 6582959B2
· Kim
· 2003
[cited by applicant]
US 6678556B1
· Nolan et al.
· 2004
[cited by applicant]
US 6680301B2
· Berg et al.
· 2004
[cited by applicant]
US 6692964B1
· June et al.
· 2004
[cited by applicant]
US 6703020B1
· Thorpe et al.
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6884879B1
· Baca et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7060269B1
· Baca et al.
· 2006
[cited by applicant]
US 7067318B2
· June et al.
· 2006
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7171264B1
· Hofmann et al.
· 2007
[cited by applicant]
US 7172869B2
· June et al.
· 2007
[cited by applicant]
US 7173116B2
· Fewell et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7569664B2
· Jakobsen et al.
· 2009
[cited by applicant]
US 7700546B2
· Mekada et al.
· 2010
[cited by applicant]
US 7754482B2
· Riley et al.
· 2010
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8017114B2
· Korman et al.
· 2011
[cited by applicant]
US 8066989B2
· Lindhofer et al.
· 2011
[cited by applicant]
US 8119129B2
· Jure-Kunkel et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8440431B2
· Voytas et al.
· 2013
[cited by applicant]
US 8440432B2
· Voytas et al.
· 2013
[cited by applicant]
US 8450471B2
· Voytas et al.
· 2013
[cited by applicant]
US 8470789B2
· Van Wetering et al.
· 2013
[cited by applicant]
US 8507443B2
· Mekada et al.
· 2013
[cited by applicant]
US 8586363B2
· Voytas et al.
· 2013
[cited by applicant]
US 8697853B2
· Voytas et al.
· 2014
[cited by applicant]
US 8722400B2
· Riley et al.
· 2014
[cited by applicant]
US 8735553B1
· Li et al.
· 2014
[cited by applicant]
US 8771985B2
· Cui et al.
· 2014
[cited by applicant]
US 9187758B2
· Cai et al.
· 2015
[cited by applicant]
US 9206404B2
· Cui et al.
· 2015
[cited by applicant]
US 9393257B2
· Osborn et al.
· 2016
[cited by applicant]
US 9555105B2
· Riley et al.
· 2017
[cited by applicant]
US 9855298B2
· Bot et al.
· 2018
[cited by applicant]
US 9861689B2
· Mach et al.
· 2018
[cited by applicant]
US 20030170238A1
· Gruenberg et al.
· 2003
[cited by applicant]
US 20030206899A1
· Ferrara et al.
· 2003
[cited by applicant]
US 20040014645A1
· Draghia-Akli et al.
· 2004
[cited by applicant]
US 20040057935A1
· Yu et al.
· 2004
[cited by applicant]
US 20050070841A1
· Mathiesen et al.
· 2005
[cited by applicant]
US 20050186208A1
· Fyfe et al.
· 2005
[cited by applicant]
US 20050196754A1
· Drmanac et al.
· 2005
[cited by applicant]
US 20060002899A1
· Rice et al.
· 2006
[cited by applicant]
US 20060009360A1
· Pifer et al.
· 2006
[cited by applicant]
US 20070041954A1
· Ichim
· 2007
[cited by applicant]
US 20070128708A1
· Gamelin
· 2007
[cited by applicant]
US 20130274134A1
· Lindstedt et al.
· 2013
[cited by applicant]
US 20150166955A1
· Van Wetering et al.
· 2015
[cited by applicant]
US 20190151363A1
· Brentjens et al.
· 2019
[cited by applicant]
US 20190263908A1
· Van Der Vliet et al.
· 2019
[cited by applicant]
US 20210322471A1
· Manting et al.
· 2021
[cited by applicant]
US 20210346479A1
· Van Wetering et al.
· 2021
[cited by applicant]
US 20210401961A1
· Manting et al.
· 2021
[cited by applicant]
US 20220023406A1
· Manting et al.
· 2022
[cited by applicant]
US 20220168407A1
· Manting et al.
· 2022
[cited by applicant]
US 20220305100A1
· Manting et al.
· 2022
[cited by applicant]
US 20230355760A1
· Manting et al.
· 2023
[cited by applicant]
US 20240002800A1
· Karlsson-Parra et al.
· 2024
[cited by applicant]
CA 3104833A1
· 2020
[cited by applicant]
EP 0666868B1
· 2002
[cited by applicant]
EP 1894575B1
· 2013
[cited by applicant]
EP 2743344A1
· 2014
[cited by applicant]
EP 2931878B1
· 2016
[cited by applicant]
WO WO1994010202A1
· 1994
[cited by applicant]
WO WO1996007432A1
· 1996
[cited by applicant]
WO WO1996013593A2
· 1996
[cited by applicant]
WO WO1996018105A1
· 1996
[cited by applicant]
WO WO1996030046A1
· 1996
[cited by applicant]
WO WO1996040200A1
· 1996
[cited by applicant]
WO WO1997027873A1
· 1997
[cited by applicant]
WO WO1998042752A1
· 1998
[cited by applicant]
WO WO1998045332A2
· 1998
[cited by applicant]
WO WO1998054311A1
· 1998
[cited by applicant]
WO WO1999018129A1
· 1999
[cited by applicant]
WO WO1999040940A1
· 1999
[cited by applicant]
WO WO2000037504A2
· 2000
[cited by applicant]
WO WO2000054708A1
· 2000
[cited by applicant]
WO WO2000054802A2
· 2000
[cited by applicant]
WO WO2001014424A2
· 2001
[cited by applicant]
WO WO2001018636A1
· 2001
[cited by applicant]
WO WO2001049317A2
· 2001
[cited by applicant]
WO WO2001093897A2
· 2001
[cited by applicant]
WO WO2002023994A1
· 2002
[cited by applicant]
WO WO2002044395A1
· 2002
[cited by applicant]
WO WO2002044396A1
· 2002
[cited by applicant]
WO WO2002092784A2
· 2002
[cited by applicant]
WO WO2003020309A2
· 2003
[cited by applicant]
WO WO2004033685A1
· 2004
[cited by applicant]
WO WO2005012359A2
· 2005
[cited by applicant]
WO WO2005026318A2
· 2005
[cited by applicant]
WO WO2005040220A1
· 2005
[cited by applicant]
WO WO2005044853A2
· 2005
[cited by applicant]
WO WO2005044857A1
· 2005
[cited by applicant]
WO WO2006000830A2
· 2006
[cited by applicant]
WO WO2006037960A2
· 2006
[cited by applicant]
WO WO2006121168A1
· 2006
[cited by applicant]
WO WO2007011693A2
· 2007
[cited by applicant]
WO WO2008119567A2
· 2008
[cited by applicant]
WO WO2009019320A2
· 2009
[cited by applicant]
WO WO2009034172A1
· 2009
[cited by applicant]
WO WO2009046541A1
· 2009
[cited by applicant]
WO WO2009101611A1
· 2009
[cited by applicant]
WO WO2009114335A2
· 2009
[cited by applicant]
WO WO2009127988A1
· 2009
[cited by applicant]
WO WO2010037838A2
· 2010
[cited by applicant]
WO WO2010070047A1
· 2010
[cited by applicant]
WO WO2011018636A2
· 2011
[cited by applicant]
WO WO2011044186A1
· 2011
[cited by applicant]
WO WO2011143624A2
· 2011
[cited by applicant]
WO WO2012056236A2
· 2012
[cited by applicant]
WO WO2012136824A1
· 2012
[cited by applicant]
WO WO2012140130A1
· 2012
[cited by applicant]
WO WO2012145493A1
· 2012
[cited by applicant]
WO WO2012170250A1
· 2012
[cited by applicant]
WO WO2013025779A1
· 2013
[cited by applicant]
WO WO2013026833A1
· 2013
[cited by applicant]
WO WO2013026837A1
· 2013
[cited by applicant]
WO WO2013067492A1
· 2013
[cited by applicant]
WO WO2013109752A1
· 2013
[cited by applicant]
WO WO2013119714A1
· 2013
[cited by applicant]
WO WO2013126794A1
· 2013
[cited by applicant]
WO WO2013181634A2
· 2013
[cited by applicant]
WO WO2014006058A1
· 2014
[cited by applicant]
WO WO2014087010A1
· 2014
[cited by applicant]
WO WO2014087248A2
· 2014
[cited by applicant]
WO WO2014090795A1
· 2014
[cited by applicant]
WO WO2014138314A1
· 2014
[cited by applicant]
WO WO2014179664A2
· 2014
[cited by applicant]
WO WO2014186469A2
· 2014
[cited by applicant]
WO WO2014191525A1
· 2014
[cited by applicant]
WO WO2014194302A2
· 2014
[cited by applicant]
WO WO2015035606A1
· 2015
[cited by applicant]
WO WO2015073801A1
· 2015
[cited by applicant]
WO WO2015085847A1
· 2015
[cited by applicant]
WO WO2015112800A1
· 2015
[cited by applicant]
WO WO2015112900A1
· 2015
[cited by applicant]
WO WO2015191861A1
· 2015
[cited by applicant]
WO WO2016022971A1
· 2016
[cited by applicant]
WO WO2016023040A1
· 2016
[cited by applicant]
WO WO2016024021A1
· 2016
[cited by applicant]
WO WO2016081423A1
· 2016
[cited by applicant]
WO WO2016109415A1
· 2016
[cited by applicant]
WO WO2016141328A2
· 2016
[cited by applicant]
WO WO2016149201A2
· 2016
[cited by applicant]
WO WO2016154628A1
· 2016
[cited by applicant]
WO WO2016176164A1
· 2016
[cited by applicant]
WO WO2016188449A1
· 2016
[cited by applicant]
WO WO2017027422A1
· 2017
[cited by applicant]
WO WO2017049251A2
· 2017
[cited by applicant]
WO WO2017053423A1
· 2017
[cited by applicant]
WO WO2017112797A1
· 2017
[cited by applicant]
WO WO2017121771A1
· 2017
[cited by applicant]
WO WO2017134140A1
· 2017
[cited by applicant]
WO WO2017180519A1
· 2017
[cited by applicant]
WO WO2017194634A1
· 2017
[cited by applicant]
WO WO2017196793A1
· 2017
[cited by applicant]
WO WO2017215585A1
· 2017
[cited by applicant]
WO WO2018017020A1
· 2018
[cited by applicant]
WO WO2018075813A1
· 2018
[cited by applicant]
WO WO2018075857A1
· 2018
[cited by applicant]
WO WO2018075960A1
· 2018
[cited by applicant]
WO WO2018089508A2
· 2018
[cited by applicant]
WO WO2018095428A1
· 2018
[cited by applicant]
WO WO2018137705A1
· 2018
[cited by applicant]
WO WO2018233575A1
· 2018
[cited by applicant]
WO WO2019027903A1
· 2019
[cited by applicant]
WO WO2019034895A1
· 2019
[cited by applicant]
WO WO2019042119A1
· 2019
[cited by applicant]
WO WO2019042285A1
· 2019
[cited by applicant]
WO WO2019042470A1
· 2019
[cited by applicant]
WO WO2019046815A1
· 2019
[cited by applicant]
WO WO2019075385A1
· 2019
[cited by applicant]
WO WO2019086573A1
· 2019
[cited by applicant]
WO WO2019108733A2
· 2019
[cited by applicant]
WO WO2019138367A1
· 2019
[cited by applicant]
WO WO2019144895A1
· 2019
[cited by applicant]
WO WO2019157843A1
· 2019
[cited by applicant]
WO WO2019173636A1
· 2019
[cited by applicant]
WO WO2019177669A1
· 2019
[cited by applicant]
WO WO2019179366A1
· 2019
[cited by applicant]
WO WO2019184912A1
· 2019
[cited by applicant]
WO WO2019185717A1
· 2019
[cited by applicant]
WO WO2019201236A1
· 2019
[cited by applicant]
WO WO2019231846A1
· 2019
[cited by applicant]
WO WO2019238012A1
· 2019
[cited by applicant]
WO WO2019241732A1
· 2019
[cited by applicant]
WO WO2020009725A1
· 2020
[cited by applicant]
WO WO2020014366A1
· 2020
[cited by applicant]
WO WO2020017962A1
· 2020
[cited by applicant]
WO WO2020019135A1
· 2020
[cited by applicant]
WO WO2020036977A1
· 2020
[cited by applicant]
WO WO2020043188A1
· 2020
[cited by applicant]
WO WO2020208054A1
· 2020
[cited by applicant]
WO WO2020217226A1
· 2020
[cited by applicant]
WO WO2021216790A1
· 2021
[cited by applicant]
Koeffler et al. (Blood. Oct. 1983; 62 (4): 709-21).
[cited by examiner]
Nagasawa et al. (J. Immunother. Nov. 2020; 8 (Suppl. 3): A102-A103; Abstract 171; pp. 1-2).
[cited by examiner]
Zuo et al. (Cells. Nov. 19, 2021; 10 (11): 3233; pp. 1-21).
[cited by examiner]
Da Costa Miranda et al. (Gynecol. Oncol. Feb. 2014; 132 (2): 287-91).
[cited by examiner]
Bamias et al. (BMC Cancer. Sep. 25, 2006: 6: 228; pp. 1-8).
[cited by examiner]
Van de Loosdrecht et al. (Cancer Immunol. Immunother. 2018; 67 (10): 1505-18).
[cited by examiner]
Leaf et al. (J. Immunother. Nov./Dec. 2017 40 (9): 315-22).
[cited by examiner]
Vermeij et al. (Clin. Dev. Immunol. 2010: 2010: 891505; pp. 1-9).
[cited by examiner]
Ning et al. (J. Biomed. Biotechnol. 2011: 2011: 172965; pp. 1-10).
[cited by examiner]
Guo et al. (Oncol. Lett. Oct. 2012; 4 (4): 595-600).
[cited by examiner]
Gupta et al. (J. Ovarian Res. Oct. 9, 2009: 2: 13; pp. 1-20).
[cited by examiner]
Dao et al. (Oncoimmunology. 2017; 6 (2): e1252895; pp. 1-10).
[cited by examiner]
Aerts-Toegaert et al., “CD83 expression on dendritic cells and T cells: Correlation with effective immune responses”, European Journal of Immunology, 37:686-695, 2007.
[cited by applicant]
Agarwal et al., In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes Molecular Therapy 28(8):1783-1794 (2020).
[cited by applicant]
Alemany, “Oncolytic Adenoviruses in Cancer Treatment”, Biomedicines 2:36-49, 2014.
[cited by applicant]
Alibakhshi et al., “Targeted cancer therapy through antibody fragments-decorated nanomedicines”, J Control Release, 2017, 268: 323-334.
[cited by applicant]
Alvey et al., “SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors”, Current Biology, 27(14):2065-207, 2017.
[cited by applicant]
Amir et al., “PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer”, Clinical Cancer Research, 17(17):5615-5625, 2011.
[cited by applicant]
Andtbacka et al., “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma”, Journal of Clinical Oncology, 2015, 22(25): 2780-2788.
[cited by applicant]
Anguille et al., “Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia”, Blood, Oct. 2017, 130(15): 1713-1721.
[cited by applicant]
Awate et al., “Mechanisms of action of adjuvants”, Frontiers in Immunology, 4(114):1-10 (2013).
[cited by applicant]
Baars et al., “Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients”, Annals of Oncology, 11(8):965-970, 2000.
[cited by applicant]
Bell et al., “Crystal structure of nucleotide-free diphtheria toxin”, Biochemistry, 1997, 36(3): 481-488.
[cited by applicant]
Bender et al., “Inactivated Influenza Virus, when Presented on Dendritic Cells, Elicits Human CD8+ Cytolytic T Cell Responses”, J. Exp. Med. 182:1663-1671 (1995).
[cited by applicant]
Bengala, et al., Mobilization; Collection, and Characterization of Peripheral Blood Hemopoietic Progenitors after Chemotherapy with Epirubicin, Paclitaxel, and Granulocyte-Colony Stimulating Factor Administered to Patie…
[cited by applicant]
Bennett et al., “Help for cytotoxic-T-cell responses is mediated by CD40 signalling”, Nature, 393:478-480 (1998).
[cited by applicant]
Bergmann et al., “An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein”, Eur J Immunol., 1993, 23(11): 2777-2781.
[cited by applicant]
Bernhard et al., Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood, Cancer Research, 1995, pp. 1099-1104, vol. 55.
[cited by applicant]
Bhaya et al., “CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation”, Annual Review Genetics, 45:273-297, 2011.
[cited by applicant]
Bikard et al., “Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system”, Nucleic Acids Research, 41(15):7429-7437, 2013.
[cited by applicant]
Bommareddy et al., “Integrating oncolytic viruses in combination cancer immunotherapy”, Nature Reviews Immunology, 2018, 18: 498-513.
[cited by applicant]
Brocks et al., “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells”, Immunotechnology 3(3):173-184 (1997).
[cited by applicant]
Bürdek et al., “Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation”, Journal of Translational Medicine, 8(90):1-13, 2010.
[cited by applicant]
Buzzi et al., “Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin”, Cancer Res., Dec. 1974, 34(12): 3481-3486.
[cited by applicant]
Buzzi et al., “CRM197: Effects of intravenous administration to advanced cancer patients”, Cancer Res., Apr. 2004, 64(7 Supplement): 878.
[cited by applicant]
Buzzi et al., “Diphtheria toxin in cancer therapy”, The Lancet, 1974, 1(7858): 628-629.
[cited by applicant]
Buzzi, “Diphtheria toxin treatment of human advanced cancer”, Cancer Res., 1982, 42(5): 2054-2058.
[cited by applicant]
Buzzi, et al., “CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients”, Cancer Immunol. Immunother., 2004, 53: 1041-1048 (2004).
[cited by applicant]
Buzzi, et al., “CRM197 and cancer: Effects of intratumoral administration”, Therapy, Sep. 2004, 1(1): 61-66.
[cited by applicant]
Buzzi, et al., “CRM197; Effects of intravenous administration to advanced cancer patients”, American Association for Cancer Research, 2004, 64(7), Supplement.
[cited by applicant]
Cermak et al, “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting”, Nucleic Acids Research, 39(12):e82-e82, 2011.
[cited by applicant]
Chang et al., “A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments”, PNAS USA 91:11408-11412 (1994).
[cited by applicant]
Chao et al., “Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies”, Frontiers in Oncology, vol. 9, Art. 1380, pp. 1-9, 2019.
[cited by applicant]
Cheever et al., “The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research”, Clinical Cancer Research, 15(17):5323-5337, 2009.
[cited by applicant]
Chen et al., “Enhanced proofreading governs CRISPR-Cas9 targeting accuracy”, Nature, 550(7676):407-410, 2017.
[cited by applicant]
Chervin et al., “Engineering higher affinity T cell receptors using a T cell display system”, The Journal of Immunology Methods 339(2):175-184 (2008).
[cited by applicant]
Cho et al., “Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease”, Nature Biotechnology, 31(3):230-232, 2013.
[cited by applicant]
Chothia et al., “The outline structure of the T-cell αβ receptor”, The EMBO Journal 7(12):3745-3755 (1988).
[cited by applicant]
Cignetti et al., CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells, Blood, 1999, pp. 2048-2055, vol. 94.
[cited by applicant]
Cohen et al., “Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR”, The Journal of Immunology 175:5799-5808 (2005).
[cited by applicant]
Cong et al., “Multiplex Genome Engineering using CRISPR/Cas Systems”, Science, 339(6121):819-823, 2013.
[cited by applicant]
Cougot et al., “‘Cap-tabolism’”, Trends in Biochemical Science 29(8):436-444, (2004).
[cited by applicant]
Cripe et al., “Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients”, Molecular Therapy, 2015, 23(3): 602-608.
[cited by applicant]
Danthinne et al., Production of first generation adenovirus vectors: a review, Gene Therapy, 7(20):1707-1714, 2000.
[cited by applicant]
Davila et al., “CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia”, PLOS ONE 8(4):e61338 (2013).
[cited by applicant]
Davis et al., “Basic Methods in Molecular Biology,” 1986.
[cited by applicant]
Davodeau et al., “Secretion of Disulfide-linked Human T-cell Receptor γδ Heterdimers”, The Journal of Biological Chemistry 268(21):15455-15460 (1993).
[cited by applicant]
DCPrime BV, “Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia”, ClinicalTrials.gov Identifier: NCT01373515, Retrieved from: <<https://clinicaltrials.gov/ct2/show/NCT01373515?term=NCT01373515&d…
[cited by applicant]
De Gruijil et al., “Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study”…
[cited by applicant]
Elango et al., “Optimized transfection of mRNA transcribed from a d(A/T)
[cited by applicant]
EPO Comms, EP 08826916.2, dated Jan. 24, 2011, Jul. 20, 2012, and May 11, 2012.
[cited by applicant]
Erben et al., “CS-1, A Novel c-kithi+ Acute Myeloid Leukemia Cell Line With Dendritic Cell Differentiation Capacity and Absent Immunogenicity”, International Journal of Cancer, 105(2):232-240, 2003.
[cited by applicant]
Ferlini et al.; A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development; Pharmacology & Toxicology 2001, 89; 231-236.
[cited by applicant]
Ferrari et al.; Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor; Cancer Immunol Immunother; 2003;…
[cited by applicant]
Fife et al., “Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist”, The Journal of Clinical Investigation 116(8):2252-2261 (2006).
[cited by applicant]
Fiorentini et al., “Clinical experience of treatment of metastatic melanoma and solid tumours adopting a derivative of diphtheria toxin: cross-reacting material 197”, In Vivo, 2013, 27(2): 197-202.
[cited by applicant]
Frietze et al., “Engineering virus-like particles as vaccine platforms”, Curr Opin Virol., 2016, 18: 44-49.
[cited by applicant]
Gaj et al., “ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering”, Trends in Biotechnology, Jul. 2013, 31(7): 1-20, (Epub May 9, 2013).
[cited by applicant]
Galluzzi et al., “Trial watch: Dendritic cell-based interventions for cancer therapy”, OncoImmunology, 1(7):1111-1134, 2012.
[cited by applicant]
Gao et al., “Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1”, Blood, 95(7):2198-2203, 2000.
[cited by applicant]
Garboczi et al., “Assembly, Specific Binding, and Crystallization of a Human TCR-αβ with an Antigenic Tax Peptide from Human T Lymphotropic Virus Type 1 and the Class I MHC Moledule HLA-A2
[cited by applicant]
Garboczi et al., “Structure of the complex between human T-cell receptor, viral peptide and HLA-A2”, Nature 384(6605):134-141 (1996).
[cited by applicant]
Garfall et al., “T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma”, Blood Advances 3(19):2812-2815 (2019).
[cited by applicant]
Geha et al., “The genetic basis of immunoglobulin-class switching”, N Engl J Med., 1994, 330(14): 1008-1009.
[cited by applicant]
Gilbert et al., “CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes”, Cell, 154(2):442-451, 2013.
[cited by applicant]
Gillis et al., “Contribution of human FcgRs to disease with evidence from human polymorphisms and transgenic animal studies”, Frontiers in Immunology 5:254 (2014).
[cited by applicant]
Giomarelli et al., “Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-I”, Thromb Haemost 97(6):955-964 (2007).
[cited by applicant]
Golden et al., “High-level production of a secreted, heterodimeric αβ murine T-cell receptor in
[cited by applicant]
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA”, Virology, 1973, 52(2): 456-467.
[cited by applicant]
Greiner et al., “High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma”, Haematologica, 95(7):1191-1197, 2010.
[cited by applicant]
Greiner et al., “Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T Cells of HLA-A2-positive patients with acute myeloid leukemia”, B…
[cited by applicant]
Grossardt et al., “Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine”, Human Gene Therapy, 2013, 24: 644-654.
[cited by applicant]
Guba, et al., “Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor”, Nature Medicine 8(2):128-135 (2002).
[cited by applicant]
Haddad, “Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery”, Frontiers in Immunology, 2017, 7: 96.
[cited by applicant]
He et al., “CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo”, Journal of Experimental & Clinical Cancer Research, 2010, …
[cited by applicant]
Hermans et al., “The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo”, Journal of Immunological Methods 285(1):25-40 (2004).
[cited by applicant]
Hermanson et al., “Utilizing chimeric antigen receptors to direct natural killer cell activity”, Frontiers in Immunology 6(195):1-6 (2015).
[cited by applicant]
Himanen et al., “Crystal structure of an Eph receptor-ephrin complex”, Nature 414(6866):933-938 (2001).
[cited by applicant]
Hirooka et al., “Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancr…
[cited by applicant]
Ho et al., “Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties”, Biochima et Biophysica Acta 1638(3):257-266 (20…
[cited by applicant]
Holler et al., “In vitro evolution of a T cell receptor with high affinity for peptide/MHC”, PNAS USA 97(10):5387-5392 (2000).
[cited by applicant]
Holler et al., “TCRs with high affinity for foreign pMHC show self-reactivity”, Nature Immunology 4(1):55-62 (2003).
[cited by applicant]
Howells et al., “Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer”, Front Oncol., 2017, 7: 195.
[cited by applicant]
Hu et al., “Evolved Cas9 variants with broad PAM compatibility and high DNA specificity”, Nature, 556(7699):57-63, 2018.
[cited by applicant]
Huang et al., “MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47”, Molecular Cancer, Jan. 24, 2018, 17(12): 1-6.
[cited by applicant]
Huck et al., “Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes”, Nucleic Acids Research 14(4):1779-1789 (1986).
[cited by applicant]
Hudecek et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity”, Cancer Immunology Research 3(2):125-135 (2015).
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Hutzler et al., “Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles”, Scientific Reports, 2017, 7: 16892.
[cited by applicant]
Hwang et al., “Controlled differentiation of stem cells”, Advanced Drug Delivery Reviews, 60(2):199-214, 2007.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2020/053898, mailed Jul. 2, 2020.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2021/052542, mailed Jun. 25, 2021.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2021/055822, mailed Sep. 30, 2021.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/NL2019/050451, mailed Oct. 4, 2019.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2008/065391, mailed Feb. 26, 2009.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2013/076067, mailed Feb. 5, 2014.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2021/052543, mailed May 31, 2021.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2021/060233, mailed Apr. 4, 2022.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2022/050555, mailed Apr. 20, 2022.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2022/052211 mailed Jul. 19, 2022.
[cited by applicant]
Jinek et al., “RNA-programmed genome editing in human cells”, eLife, 2:e00471, 2013.
[cited by applicant]
Jores et al., “Resolution of hypervariable regions in T-cell receptor β chains by a modified Wu-Kabat index of amino acid diversity”, PNAS USA 87:9138-9142 (1990).
[cited by applicant]
Jurincic-Winkler et al., “Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma”, Anticancer Res., 1996, 16(4A): 2105-2110.
[cited by applicant]
Kalinski et al., “Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses”, Nature Review 5:251-260 (2005).
[cited by applicant]
Kleinstiver et al., “High-fidelity CRISPR-CAS9 variants with undetectable genome-wide off-targets,” Nature, 529(7587):490-495, 2016.
[cited by applicant]
Kloosterman et al., “Deciphering the pathogenic consequences of chromosomal aberrations in human genetic disease”, Molecular Cytogenetics, 7(100):1-12, 2014.
[cited by applicant]
Kochenderfer et al., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, Journal of Immunotherapy 32(7):689-702 (2009).
[cited by applicant]
Kohrt et al., “Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation”, Blood, 118(19):5319-5329, 2011.
[cited by applicant]
Kotb, “Bacterial Pyrogenic Exotoxins as Superantigens”, Clinical Microbiology Reviews 8(3):411-426 (1995).
[cited by applicant]
Koup et al., “Vaccine design for CD8 T lymphocyte responses”, Cold Spring Harb Perspect Med., 2011, 1(1): a007252.
[cited by applicant]
Krug et al., “WT1 Peptide Vaccinations Induce CD4 and CD8 T Cell Immune Responses in Patients With Mesothelioma and Non-small Cell Lung Cancer”, Cancer Immunology, Immunotherapy, 59(10):1467-1479, 2010.
[cited by applicant]
Kruisbeek, “Adoption of Cryostor® in Manufacturing of a Dendritic Cell Vaccine Platform”, BioPreservation Today®, vol. 3, Issue 1, p. 10, 2011.
[cited by applicant]
Kudo-Saito, et al., “Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules”, Clin Cancer Res., 2004, 10(…
[cited by applicant]
Kurtzberg et al., “CD7+, CD4−, CD8-Acute Leukemia: A Syndrome of Malignant Pluripotent Lymphohematopoietic Cells”, Blood, 73(2):381-390, 1989.
[cited by applicant]
Lal et al., “Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy”, Cancer Gene Ther., 2018, 25: 216-226.
[cited by applicant]
Larsson et al., “Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells”, Immunology, 117:156-166, 2006.
[cited by applicant]
Laurell et al., “Intratumorally injection pro-inflammatory allogeneic dendritic cells as immune enhancers: a first in-human study in unfavourable risk patients with metastatic renal cell carcinoma”, Journal for Immunoth…
[cited by applicant]
Lawler et al., “Oncolytic Viruses in Cancer Treatment: A Review”, JAMA Oncol. Review, 2017, 3(6): 841-849.
[cited by applicant]
Leaf et al., “DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma”, Journal of Immunotherapy 40(9):315-322 (2017).
[cited by applicant]
Lee et al., “ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells”, Biology of Blood and Marrow Transplantation 25:625-638, doi.org/10.1016/j.bbmt.2018.12.7…
[cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Developmental and Comparative Immunology 27:55-77 (2003).
[cited by applicant]
Li et al., “Directed evolution of human T-cell receptors with picomolar affinities by phage display”, Nature Biotechnology 23(3):349-354 (2005).
[cited by applicant]
Li et al., “Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice”, Nature Communications, 11:581, 2020.
[cited by applicant]
Liu et al., “Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential”, PLoS One, 10(9): e0137345, 2015.
[cited by applicant]
Logtenberg et al., “Glutaminyl cyclase in an enzymatic modifier of the CD47-SIRPα axis and target for cancer immunotherapy”, Nat. Med., 25(4):612-619, 2019.
[cited by applicant]
Lu et al., “Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies”, OncoTargets and Therapy, 13:9323-9331, 2020.
[cited by applicant]
Lundstrom, K., “Viral Vectors in Gene Therapy”, Diseases 6(2):42, DOI: 10.3390/diseases6020042 (2018).
[cited by applicant]
Ma et al., “Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential”, Journal of Nanobiotechnology, 18:12, pp. 1-15, 2020.
[cited by applicant]
Mali et al., “CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering”, Nature Biotechnology, 31(9):833-838, 2013.
[cited by applicant]
Mali et al., “RNA-Guided Human Genome Engineering via Cas9”, Science, 339(6121):823-826, 2013.
[cited by applicant]
Malito et al., “Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197”, Proc Natl Acad Sci U S A, 2012, 109(14): 5229-5234.
[cited by applicant]
Marelli et al., “Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer”, Frontiers in Immunology, 2018, 9: 866.
[cited by applicant]
Masterson et al., “MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors”, Blood, 100(2):701-703, 2002.
[cited by applicant]
May et al., “Peptide Epitopes From the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells”, Clinical Cancer Research, 13(15):4547-4555, 2007.
[cited by applicant]
Mishra et al., “Structural and immunological characterization of
[cited by applicant]
Mitchell et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients”, Nature 519(7543):366-369 (2015).
[cited by applicant]
Miyamoto et al., “Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy”, Cancer Science 97(5):341-347 (2006).
[cited by applicant]